IMMUNE STATE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT LATE TERMS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

Abstract. Autologous hematopoietic stem cell transplantation (auto-HSCT) is one of the most effective methods for treatment of patients with various forms of hemoblastoses, both in adults and children. However, high-dose chemotherapy protocols used in this procedure are characterized by pronounced m...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	N. V. Minaeva, T. P. Zagoskina, E. P. Svedentsov, G. A. Zaitceva, N. V. Isaeva, N. А. Zorina
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	high-dose chemotherapy stem cell transplantation hematopoietic stem cell immune state late post-transplant period Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/6a53315e671e45e58d550dcbb5a59886
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6a53315e671e45e58d550dcbb5a59886
record_format	dspace
spelling	oai:doaj.org-article:6a53315e671e45e58d550dcbb5a598862021-11-18T08:03:42ZIMMUNE STATE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT LATE TERMS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION1563-06252313-741X10.15789/1563-0625-2012-6-519-526https://doaj.org/article/6a53315e671e45e58d550dcbb5a598862014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/611https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Autologous hematopoietic stem cell transplantation (auto-HSCT) is one of the most effective methods for treatment of patients with various forms of hemoblastoses, both in adults and children. However, high-dose chemotherapy protocols used in this procedure are characterized by pronounced myeloand immunotoxicity. Appropriate data concerning immune state at long terms after high-dose chemotherapy and auto-HSCT are sparse and controversial, and there is no consensus on time dynamics of immune system reconstitution. The aim of this study was a comprehensive evaluation of immunity in recipients of auto-HSCT at longer terms. Clinical and immunological testing was performed in ninety-eight patients with hematological malignancies before starting a high-dose chemotherapy, and at late post-transplant period. The state of cellular immunity was assessed as expression of surface CD3+, CD4+, CD8+, CD16+, CD19+ lymphocyte antigens. Humoral immunity was evaluated by serum IgG, IgA, and IgM levels. The studies have revealed disorders of cellular and humoral immunity, as well as nonspecific immune resistance factors in recipients of autologous hematopoietic stem cells at late terms post-transplant. Immune reconstitution in patients receiving highdose consolidation treatment followed by auto-HSCT takes longer time than in patients who did not receive autologous hematopoietic stem cells. Severity of these disturbances and immune reconstitution rates depend on the type of conditioning regimen, and the source of haematopoietic stem cells used for transplantation.N. V. MinaevaT. P. ZagoskinaE. P. SvedentsovG. A. ZaitcevaN. V. IsaevaN. А. ZorinaSPb RAACIarticlehigh-dose chemotherapystem cell transplantationhematopoietic stem cellimmune statelate post-transplant periodImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 14, Iss 6, Pp 519-526 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	high-dose chemotherapy stem cell transplantation hematopoietic stem cell immune state late post-transplant period Immunologic diseases. Allergy RC581-607
spellingShingle	high-dose chemotherapy stem cell transplantation hematopoietic stem cell immune state late post-transplant period Immunologic diseases. Allergy RC581-607 N. V. Minaeva T. P. Zagoskina E. P. Svedentsov G. A. Zaitceva N. V. Isaeva N. А. Zorina IMMUNE STATE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT LATE TERMS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
description	Abstract. Autologous hematopoietic stem cell transplantation (auto-HSCT) is one of the most effective methods for treatment of patients with various forms of hemoblastoses, both in adults and children. However, high-dose chemotherapy protocols used in this procedure are characterized by pronounced myeloand immunotoxicity. Appropriate data concerning immune state at long terms after high-dose chemotherapy and auto-HSCT are sparse and controversial, and there is no consensus on time dynamics of immune system reconstitution. The aim of this study was a comprehensive evaluation of immunity in recipients of auto-HSCT at longer terms. Clinical and immunological testing was performed in ninety-eight patients with hematological malignancies before starting a high-dose chemotherapy, and at late post-transplant period. The state of cellular immunity was assessed as expression of surface CD3+, CD4+, CD8+, CD16+, CD19+ lymphocyte antigens. Humoral immunity was evaluated by serum IgG, IgA, and IgM levels. The studies have revealed disorders of cellular and humoral immunity, as well as nonspecific immune resistance factors in recipients of autologous hematopoietic stem cells at late terms post-transplant. Immune reconstitution in patients receiving highdose consolidation treatment followed by auto-HSCT takes longer time than in patients who did not receive autologous hematopoietic stem cells. Severity of these disturbances and immune reconstitution rates depend on the type of conditioning regimen, and the source of haematopoietic stem cells used for transplantation.
format	article
author	N. V. Minaeva T. P. Zagoskina E. P. Svedentsov G. A. Zaitceva N. V. Isaeva N. А. Zorina
author_facet	N. V. Minaeva T. P. Zagoskina E. P. Svedentsov G. A. Zaitceva N. V. Isaeva N. А. Zorina
author_sort	N. V. Minaeva
title	IMMUNE STATE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT LATE TERMS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
title_short	IMMUNE STATE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT LATE TERMS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
title_full	IMMUNE STATE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT LATE TERMS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
title_fullStr	IMMUNE STATE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT LATE TERMS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
title_full_unstemmed	IMMUNE STATE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT LATE TERMS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
title_sort	immune state in patients with hematological malignancies at late terms after autologous hematopoietic stem cell transplantation
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/6a53315e671e45e58d550dcbb5a59886
work_keys_str_mv	AT nvminaeva immunestateinpatientswithhematologicalmalignanciesatlatetermsafterautologoushematopoieticstemcelltransplantation AT tpzagoskina immunestateinpatientswithhematologicalmalignanciesatlatetermsafterautologoushematopoieticstemcelltransplantation AT epsvedentsov immunestateinpatientswithhematologicalmalignanciesatlatetermsafterautologoushematopoieticstemcelltransplantation AT gazaitceva immunestateinpatientswithhematologicalmalignanciesatlatetermsafterautologoushematopoieticstemcelltransplantation AT nvisaeva immunestateinpatientswithhematologicalmalignanciesatlatetermsafterautologoushematopoieticstemcelltransplantation AT nazorina immunestateinpatientswithhematologicalmalignanciesatlatetermsafterautologoushematopoieticstemcelltransplantation
_version_	1718422482358108160

IMMUNE STATE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT LATE TERMS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

Ejemplares similares